Dr. Michael Roizen Longevity Protocol: How a Regular Patient Gets Access

Who Is Dr. Michael Roizen and Why Does His Protocol Matter?

Dr. Michael Roizen is a board-certified internist and anesthesiologist who spent more than a decade as Cleveland Clinic's inaugural Chief Wellness Officer before transitioning to an emeritus role. He is best known for developing the RealAge biological-age scoring system, first described in his 1999 book, and for co-authoring a series of bestselling health books with Dr. Mehmet Oz.

His relevance to longevity medicine extends beyond celebrity. Roizen has published peer-reviewed work and has sat on editorial boards focused on preventive cardiology and metabolic health. When he discusses his personal medication and supplement choices in interviews and podcasts, physicians and patients pay attention because his claims are traceable to specific trials.

The RealAge Framework

The RealAge model attempts to translate lifestyle and biomarker data into a single "biological age" number that can diverge substantially from chronological age. A 60-year-old with optimal lipids, low hsCRP, regular aerobic exercise, and non-smoker status might register a RealAge of 48 under the scoring system.

The framework has drawn criticism for its commercial ties, but the underlying biology has partial support. A 2023 analysis in Nature Aging found that multi-omic biological clocks predict all-cause mortality better than chronological age alone. [1] Roizen's public positioning predates these molecular clocks by two decades, which gives his lay framing some retrospective scientific credibility.

His Role at Cleveland Clinic

Cleveland Clinic runs one of the most recognized Executive Health programs in the United States. Roizen helped design that program's emphasis on prevention-first medicine, placing wellness screenings and lifestyle counseling alongside traditional disease management. His influence on the clinic's protocols gives weight to what he personally practices, because those practices informed the clinical environment he built.

What Dr. Michael Roizen Has Said He Takes

Roizen has discussed his personal health regimen in multiple public forums, including the Dr. Oz Show, the Longevity Lab podcast, and his own books. The following is drawn from those stated sources. Where inference is required, it is labeled as such.

Metformin Off-Label for Longevity

In interviews promoting his book AgeProof (2017), Roizen stated he takes metformin, the biguanide diabetes drug, off-label for anti-aging purposes. This puts him in the company of researchers like Dr. Nir Barzilai, the principal investigator of the TAME (Targeting Aging with Metformin) trial, which is an NIH-funded Phase 3 study testing whether metformin delays the onset of age-related diseases in non-diabetic adults aged 65-79. [2]

Metformin's proposed longevity mechanism involves AMPK activation, mTOR inhibition, and modest reductions in circulating IGF-1. An observational analysis published in Aging Cell (2014, N=78,241) found that diabetic patients on metformin had lower all-cause mortality than matched non-diabetic controls not on the drug, a finding that generated enormous interest in the longevity community. [3]

Roizen's reported dose, consistent with off-label longevity use in the literature, is 500-1,000 mg daily, well below the maximum therapeutic diabetes dose of 2,550 mg. Standard prescribing cautions still apply: renal function must be monitored, and the drug is contraindicated at eGFR <30 mL/min/1.73m².

Omega-3 Fatty Acids

Roizen has consistently recommended high-dose omega-3 supplementation in his books and media appearances, citing cardiovascular and inflammatory endpoints. The REDUCE-IT trial (N=8,179) showed that icosapentaenoic acid (EPA) 4 g/day as prescription icosapent ethyl (Vascepa) reduced major adverse cardiovascular events by 25% in statin-treated patients with elevated triglycerides, with a hazard ratio of 0.75 (95% CI 0.68-0.83, P<0.001). [4]

Roizen's publicly stated regimen reportedly includes 2-4 g/day of EPA+DHA combined. Whether he uses prescription icosapent ethyl or an over-the-counter fish oil concentrate is not clearly documented in public sources. This detail should be confirmed by a treating physician before any patient replicates the approach.

Vitamin D3

In AgeProof and related media, Roizen has cited vitamin D sufficiency as a longevity variable. The VITAL trial (N=25,871) tested vitamin D3 at 2,000 IU/day against placebo over a median 5.3 years and found a 13% reduction in cancer mortality (HR 0.87, 95% CI 0.70-1.06) that reached significance in follow-up analyses, alongside a 7% reduction in major cardiovascular events that did not meet the primary endpoint. [5]

Roizen's stated target serum 25-OH vitamin D level is 50-80 ng/mL, which is above the conventional sufficiency threshold of 20 ng/mL and above the Institute of Medicine's cautious upper target of 50 ng/mL. Some endocrinologists argue the 50-80 ng/mL target lacks randomized trial support for all-cause mortality benefit. Patients should test their baseline level and work with a physician to determine a personalized dose.

CoQ10 and Other Supplements

Roizen has mentioned coenzyme Q10 (100-200 mg/day) in the context of mitochondrial support, particularly for patients on statins, who may have modestly reduced endogenous CoQ10 synthesis. A 2018 meta-analysis in the Journal of the American Heart Association (12 trials, N=694) found that CoQ10 supplementation reduced statin-associated muscle symptoms, though effect sizes were modest. [6]

He has also referenced resveratrol (at doses of 250-500 mg/day) in older media appearances, though he appears to have moderated that position as the David Sinclair-era enthusiasm for high-dose resveratrol has been tempered by pharmacokinetic data showing poor oral bioavailability.

Aspirin: A Protocol That Changed

Roizen was an early and vocal advocate of low-dose aspirin (81 mg/day) for primary cardiovascular prevention. He revised this position publicly after the ASPREE trial (N=19,114, median age 74) showed that aspirin in healthy older adults increased major bleeding risk without a statistically significant reduction in cardiovascular events or all-cause mortality, with a hazard ratio for all-cause mortality of 1.14 (95% CI 1.01-1.29) driven largely by cancer-related deaths. [7] His willingness to update his protocol in response to trial data is worth noting for patients who want to know how he thinks about evidence.

The Cleveland Clinic Executive Health Model

Cleveland Clinic's Executive Health Program (located in Cleveland, Ohio, and with a satellite presence in several U.S. Cities) is the formal institutional route to getting a workup similar to what Roizen helped design. A standard Executive Health visit at Cleveland Clinic includes a comprehensive physical, same-day specialist consultations, advanced lipid testing, cardiac imaging if indicated, and a personalized prevention plan delivered in one to two days.

What the Workup Typically Includes

A longevity-oriented workup at Cleveland Clinic or a comparable executive health program generally covers:

• Full metabolic panel including fasting glucose and HbA1c
• Advanced lipid panel (LDL particle number, ApoB, Lp(a))
• Inflammatory markers: hsCRP, IL-6, fibrinogen
• Hormonal panel: testosterone (total and free), DHEA-S, thyroid panel (TSH, free T3, free T4)
• Body composition via DEXA scan
• Cardiorespiratory fitness via VO2 max testing
• Coronary artery calcium (CAC) score for patients over 40 with cardiac risk factors
• Cognitive screening

The cost for the Cleveland Clinic Executive Health two-day program runs approximately USD 2,000-4,000 out of pocket, as most commercial insurers do not cover preventive-only visits of this scope.

Geographical and Financial Barriers

Most Americans do not live near a Cleveland Clinic campus, and a USD 3,000+ out-of-pocket visit is inaccessible to most households. This creates a real gap between the longevity protocols Roizen publicly endorses and what the average patient can access. The gap has shrunk considerably since 2020, largely because of telehealth expansion.

How a Regular Patient Accesses a Comparable Protocol

The following decision framework is developed by the HealthRX medical team to map access routes by cost and depth of workup. It does not replicate the full Cleveland Clinic program but covers the evidence-based core elements Roizen has discussed publicly.

Step 1: Baseline Lab Panel (USD 150-400)

Order through your primary care physician or a direct-to-consumer lab service (e.g., Quest Diagnostics or LabCorp without a physician intermediary in states that allow it). Target biomarkers:

• HbA1c and fasting glucose (to determine metformin candidacy)
• ApoB and Lp(a) (stronger predictors of ASCVD than LDL-C alone per 2018 AHA/ACC guidelines) [8]
• hsCRP (cardiovascular inflammation proxy)
• 25-OH vitamin D
• Serum testosterone and free testosterone if symptoms suggest deficiency
• TSH

Step 2: Interpret Results With a Longevity-Focused Clinician (USD 100-300 per visit)

Functional medicine physicians, preventive cardiologists, and longevity-focused internists can interpret these results in a prevention context rather than waiting for disease thresholds to be crossed. The American College of Preventive Medicine and the American College of Lifestyle Medicine both maintain physician directories.

Telehealth platforms specializing in metabolic and longevity medicine can schedule an initial consultation within days and, in most states, prescribe metformin, GLP-1 agonists, or other longevity-adjacent medications after a synchronous video visit.

Step 3: Address the Modifiable Lifestyle Variables First

Roizen has repeatedly stated in his books and on-camera interviews that no supplement or drug outperforms consistent exercise, sleep, and dietary quality for biological age. The CALERIE-2 trial (N=218) showed that 25% caloric restriction over two years reduced multiple markers of metabolic syndrome and lowered core body temperature, a proposed longevity biomarker, without adverse effects on bone mineral density or quality of life. [9]

His publicly stated personal exercise target is approximately 10,000 steps per day plus three to four resistance training sessions per week. That aligns with current AHA guidelines recommending 150 minutes of moderate-intensity or 75 minutes of vigorous aerobic activity weekly, plus two days of muscle-strengthening. [10]

Step 4: Discuss Prescription Options With Your Physician

For patients with a fasting glucose of 100-125 mg/dL (prediabetes) or HbA1c of 5.7-6.4%, off-label metformin is arguably the most evidence-adjacent longevity prescription currently available while TAME results are pending. The American Diabetes Association's 2024 Standards of Medical Care note that metformin may be considered in people with prediabetes, particularly those under 60, with BMI >35, or with a history of gestational diabetes. [11]

GLP-1 receptor agonists (semaglutide, tirzepatide) have emerged since Roizen's most recent book as metabolically relevant agents. Semaglutide 2.4 mg (Wegovy) produced 14.9% mean weight loss at 68 weeks vs. 2.4% on placebo in STEP-1 (N=1,961, P<0.001). [12] The SELECT trial (N=17,604) subsequently showed semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in non-diabetic adults with established cardiovascular disease and BMI >27, independent of weight change. [13] Roizen has not publicly commented on GLP-1 agonists for longevity as of the date of this article's review, but the cardiovascular and metabolic data are consistent with the prevention framework he has publicly championed.

Step 5: Retest at 6 and 12 Months

Longevity protocols are not static prescriptions. Biomarker response varies substantially by individual. A patient who starts vitamin D3 at 2,000 IU/day may reach 45 ng/mL while another may reach 65 ng/mL on the same dose. Retesting at six months allows dose titration before any harm from excess accrues.

What the Evidence Actually Supports vs. What Is Still Experimental

Roizen has been careful in some forums to distinguish what he calls "proven" from "promising," though lay-audience books inevitably compress that nuance.

Well-Supported Interventions

| Intervention | Key Trial | Magnitude of Benefit | |---|---|---| | Metformin in prediabetes (diabetes prevention) | DPP (N=3,234) | 31% reduction in diabetes incidence vs. Placebo [14] | | Omega-3 (prescription EPA) for high-CV-risk patients | REDUCE-IT (N=8,179) | 25% reduction in MACE [4] | | Vitamin D3 2,000 IU/day (cancer mortality) | VITAL (N=25,871) | 13% reduction in cancer mortality [5] | | Aerobic exercise (all-cause mortality) | Multiple RCTs; AHA meta-analysis | ~30% reduction in all-cause mortality vs. Sedentary controls [10] |

Experimental or Weakly Supported

• Resveratrol at high doses: Phase 2 trials have not replicated animal-model longevity findings in humans. Bioavailability remains poor without proprietary formulations.
• NAD+ precursors (NMN, NR): Small human trials show increases in blood NAD+ levels but no long-term outcome data exist. TAME-equivalent outcome trials are not yet running for these agents.
• Senolytics (dasatinib plus quercetin): Promising Phase 1 data from Mayo Clinic in senescence-related conditions, but no randomized evidence for longevity extension in healthy humans.

Direct Quote From the Longevity Field

Dr. Nir Barzilai, principal investigator of the TAME trial and director of the Institute for Aging Research at Albert Einstein College of Medicine, stated in a 2021 interview with the Journal of the American Geriatrics Society: "Metformin is the only drug we have right now that has enough epidemiological and mechanistic evidence to warrant a properly powered aging trial. That is exactly what TAME is designed to provide." [2]

This quote contextualizes Roizen's personal metformin use as consistent with the leading edge of academic longevity science rather than as fringe self-experimentation.

Practical Cost Breakdown for Patients

| Route | Estimated Annual Cost (USD) | What You Get | |---|---|---| | Cleveland Clinic Executive Health (two-day) | 2,500-4,500 | Comprehensive same-day workup, specialist consultations | | Longevity-focused internist (in-person, 2 visits/yr) | 600-1,500 | Personalized panel, prescription access, follow-up | | Telehealth longevity platform (HealthRX or comparable) | 300-900 | Video consult, labs ordered, rx if indicated | | DIY labs plus PCP visit | 200-500 | Basic panel; depends on PCP willingness to engage with longevity framing |

Costs do not include prescription medications. Generic metformin 500 mg costs approximately USD 4-10/month at major U.S. Pharmacies without insurance.